TAMPA, Fla. and LONDON, Dec. 30, 2025 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (Nasdaq: AKTX), an oncology biotechnology ...

Q4 2025 showcased the industry’s pivot toward precise biology, localised delivery, and earlier intervention – with multiple ...

Akari Therapeutics, Plc (Nasdaq: AKTX), an oncology biotechnology company developing antibody drug conjugates (ADCs) with novel payloads today ...

Beijing Zhongwei Sail Technology Co., Ltd. ("ZW-Sail"), a pioneer in Micro LED semiconductor micro-display systems, today announced the successful tape-out of its first process verification chip.

No treatment-related adverse toxicity was observed across completed GLP studies, with consistent systemic exposure following ...

Longevity science has spent decades chasing single molecules that might slow aging, but most candidates have delivered modest ...

Metabolic reprogramming in the tumor microenvironment shapes immune function and therapy resistance, offering insights into ...

Discusses Year-End Late-Stage Pipeline Review With Focus on Clinical and Regulatory Developments December 16, 2025 11:15 AM ...

Vistagen , a late clinical-stage biopharmaceutical company pioneering neuroscience with nose-to-brain neurocircuitry to develop and commercialize a new class of intranasal product candidates called ...

Hepatocellular carcinoma (HCC) remains a leading cause of cancer-related mortality worldwide, driven by marked molecular and clinical heterogeneity and ...

The interstellar comet 3I/ATLAS has started to brighten and dim in a remarkably steady rhythm, repeating every 16.16 hours as it sweeps through the inner solar system. That optical heartbeat has drawn ...

In the expanding field of peptide-based research, a combination of two bioactive molecules—BPC‑157 and TB‑500—has garnered ...